A prospective multi-center randomized comparative trial evaluating outcomes of transrectal ultrasound (TRUS)-guided 12-core systematic biopsy, mpMRI-targeted 12-core biopsy, and artificial intelligence ultrasound of prostate (AIUSP) 6-core targeted biopsy for prostate cancer diagnosis
Xiao Wang(Qingdao University), Liping Xie(First Affiliated Hospital Zhejiang University), Xueyou Ma(First Affiliated Hospital Zhejiang University), Weizhi Zhu(Ningbo No. 2 Hospital), Hongtao Cheng(University of Science and Technology of China), Gang Wang(Jiangsu University), Hong Chen(Northeast Forestry University), Ben Liu(Yichun University), Fang Ye(Ningbo No. 2 Hospital), Guobin Weng(Ningbo Medical Center Lihuili Hospital), Jiangfeng Li(First Affiliated Hospital Zhejiang University), Jianjian Xiang(Zhejiang University), Yanqi Xie(Second Affiliated Hospital of Zhejiang University), Xiangyi Zheng(Tianjin University)
Cited by 26
Related Papers
The Lancet Commission on prostate cancer: planning for the surge in cases
|The Lancet|2024|694
YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer
|Molecular Cancer|2020|383
Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis
|World Journal of Surgical Oncology|2019|276